Experienced in Prostate Cancer

Vilnis Lietuvietis

Hipokrata Street 2, 
Riga, RIX, LV 
Experienced in Prostate Cancer
Hipokrata Street 2, 
Riga, RIX, LV 
OverviewLocationsClinical Research

Overview

Vilnis Lietuvietis practices in Riga, Latvia. Lietuvietis is rated as an Experienced expert by MediFind in the treatment of Prostate Cancer. Their top areas of expertise are Prostate Cancer, Non-Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), and Enlarged Prostate (BPH).

Their clinical research consists of co-authoring 23 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 12 articles in the study of Prostate Cancer.

Locations

Hipokrata Street 2, Riga, RIX LV1038, Latvia
Other Locations
Dzirciema Str 16, Riga, RIX LV1007, Latvia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug
Study Drug: UGN-102
Study Phase: Phase 3
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Enrollment Status: Terminated
Publish Date: June 06, 2024
Intervention Type: Drug, Procedure
Study Drug: Mitomycin C
Study Phase: Phase 3
View 1 Less Clinical Trial

23 Total Publications

Testicular cancer in Latvia: incidence trends and prognostic outcomes across a 23-year study.
Testicular cancer in Latvia: incidence trends and prognostic outcomes across a 23-year study.
Journal: BMC cancer
Published: February 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lietuvietis's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile